Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial

被引:0
作者
Yao Xie DaoZhen Xu ZhiMeng Lu KangXian Luo JiDong Jia YuMing Wang GuiZhen Zhao ShuLin Zhang and DaZhi Zhang Beijing China Ninth Clinical Department Beijing Ditan Hospital Beijing China [100011 ]
Department of Infectious Dis eases Ruijin Hospital Shanghai China [200025 ]
Department of Infectious Diseases Nanfang Hospital First Military Medical University Guangzhou China [510515 ]
Center of Liver Diseases Beijing Friendship Hospital Beijing China [100050 ]
Institute of Infectious Diseases Southwest Hospital Third Military Medical University Chongqing China [400038 ]
Department of Infectious Disea ses Second Hospital China Medical University Shenyang China [110004 ]
Department of Infectious Diseases First Affiliated Hospital Xian Jiaotong University Xian China [710061 ]
and Liver Disease Center of Chongqing Second Affiliated Hospital Chongqing Medi cal University Chongqing China [400010 ]
机构
关键词
hepatitis C virus; chronic hepatitis C; interferon; peg-IFN; genotype;
D O I
暂无
中图分类号
R512.63 [];
学科分类号
100401 ;
摘要
BACKGROUND: This study was undertaken to investigate the predictive factors of sustained viral response in roferon- A or pegasys treated chronic hepatitis C patients after logis- tic regression analysis of the factors that might be associated with the therapeutic effects of interferon (IFN). METHODS: All patients enrolled into this randomized, open and multi-center controlled trial were divided into two groups randomly and treated with pegasys and roferon- A for 24 weeks, then followed up for another 24 weeks. Be- fore treatment, hepatitis C virus (HCV) genotype was de- termined, and HCV-RNA in serum was detected before and at the end of treatment and follow-up. HCV-RNA turning negative was considered the major index for evaluat- ing the therapeutic effect. The clinical characteristics inclu- ding gender, age, infection route of HCV, treatment with IFN, platelet count, AST/ALT ratio and treatment drugs were analyzed by logistic regression. RESULTS: Intention to treat (ITT) and per-protocol (PP) population groups have 208 and 197 patients respectively. In the PP group, after treatment for 24 weeks, the response rates of female patients aged less than 50 years, infected through non-transfusion, relapsed after IFN treatment, and presented with a AST/ALT ratio sgl, virus load less than 8 × 105 IU/ml, and non genotype 1 HCV infection, and treated finally with pegasys were higher than those of male pa- tients, aged more than 50 years, infected by transfusion, treated firstly with IFN, presented with a AST/ALT rations 1, virus load equal or more than 8 × 105 IU/ml, and geno- type 1 infection, and treated finally with roferon-A. But, at the end of follow-up, the patients with a AST/ALT ration 1 and virus load more than 8 ×105 IU/ml had a higher rate of sustained response than did those with a AST/ALT ratio ^1 and virus load less than 8 ×105 IU/ml. Logistic regres- sion analysis and control of the promiscuous factors showed that the genotype of HCV was not related to the response rate at the end of treatment (OR 0.604, 95% CI 0.271- 1.349, P =0.219), but was the independent predictive fac- tor of virus sustained response to IFN treatment ( OR 0.408, 95% CI 0.189-0.881, P =0.023). The form of IFN was significantly related to viral response at the end of treat- ment (OR0.105, 95% CI 0.052-0.212, P<0.001), and pe- gasys were an intensely predictive factor for sustained re- sponse (OR 0.255, 95% CI 0. 123-0.529, P<0.001). CONCLUSION: HCV genotype and pegasys are the predic- tive factors for IFN response to the IFN treatment of pa- tients with chronic hepatitis C.
引用
收藏
页码:213 / 219
页数:7
相关论文
共 16 条
[1]  
Pegylated Interferon Monotherapy for Chronic Hepatitis C[J] . Jenny Heathcote,Stefan Zeuzem.Semin Liver Dis . 2004 (S 2)
[2]   High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C [J].
Moskovitz, DN ;
Manoharan, P ;
Heathcote, EJ .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 17 (08) :479-482
[3]   High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load [J].
Tsubota, A ;
Arase, Y ;
Suzuki, F ;
Suzuki, Y ;
Akuta, N ;
Hosaka, T ;
Someya, T ;
Kobayashi, M ;
Saitoh, S ;
Ikeda, K ;
KumadA', H .
JOURNAL OF GASTROENTEROLOGY, 2004, 39 (02) :155-161
[4]   Pilot study of prolonged interferon-α retreatment in chronic hepatitis C patients with genotype 1b [J].
Nomura, H ;
Tanimoto, H ;
Sou, S ;
Nagahama, T ;
Hayashi, J ;
Kashiwagi, S ;
Ishibashi, H .
HEPATOLOGY RESEARCH, 2003, 27 (04) :266-271
[5]   Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage [J].
Serra, MA ;
Rodríguez, F ;
del Olmo, JA ;
Escudero, A ;
Rodrigo, JM .
JOURNAL OF VIRAL HEPATITIS, 2003, 10 (03) :183-188
[6]   Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C [J].
Fattovich, G ;
Zagni, I ;
Fornaciari, G ;
Minola, E ;
Fabris, P ;
Boccia, S ;
Giusti, M ;
Abbati, G ;
Felder, M ;
Rovere, P ;
Redaelli, A ;
Tonon, A ;
Montanari, R ;
Paternoster, C ;
Distasi, M ;
Castagnetti, E ;
Tositti, G ;
Rizzo, C ;
Suppressa, S ;
Pantalena, M ;
Lomonaco, L ;
Scattolini, C ;
Tagger, A .
JOURNAL OF VIRAL HEPATITIS, 2003, 10 (02) :111-117
[7]   Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load [J].
Arase, Y ;
Ikeda, K ;
Tsubota, A ;
Suzuki, Y ;
Saitoh, S ;
Kobayashi, M ;
Kobayashi, M ;
Suzuki, F ;
Akuta, N ;
Someya, T ;
Kumada, H .
JOURNAL OF GASTROENTEROLOGY, 2003, 38 (02) :158-163
[8]   The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C [J].
Myers, RP ;
Patel, K ;
Pianko, S ;
Poynard, T ;
McHutchison, JG .
JOURNAL OF VIRAL HEPATITIS, 2003, 10 (01) :16-22
[9]   The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis [J].
Giannini, E ;
Botta, F ;
Testa, E ;
Romagnoli, P ;
Polegato, S ;
Malfatti, F ;
Fumagalli, A ;
Chiarbonello, B ;
Risso, D ;
Testa, R .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (11) :2855-2860
[10]   High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis [J].
Mangia, A ;
Santoro, R ;
Piatelli, M ;
Leandro, G ;
Minerva, N ;
Annese, M ;
Bacca, D ;
Spirito, F ;
Carretta, V ;
Ventrella, F ;
Cela, M ;
Andriulli, A .
JOURNAL OF HEPATOLOGY, 2002, 37 (01) :109-116